Know your DJD product Options

Which joint health products can you trust to keep horses moving?
### Not all products are created equally

<table>
<thead>
<tr>
<th>FDA-approved drug requirements</th>
<th>Clinical safety &amp; efficacy</th>
<th>Consistent formulation</th>
<th>Advertising submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequan i.m. - Polysulfated Glycosaminoglycan</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>

**Only one FDA-approved polysulfated glycosaminoglycan**

No generic equivalent

**Equine Hyaluronate Sodium (HAs)**

**Brand name and generic Rx products**

A few examples: HYVISC® [hyaluronate sodium] LEGEND™ [hyaluronate sodium] HYALOVET® [hyaluronate sodium]

Not PSGAG

**Medical Devices**

None are FDA-cleared joint treatments

A few examples: ICHON™ Chondroprotect™ HYCOAT® Hytryl® Map® 5 Pentosan Polysulfate Polyglycan®

Not FDA-required, but recommended

**Compounded Injectables**

Special-case custom formulations

A few examples: Compounded acetyl-d-glucosamine injection Compounded HA injection "Cocktail" injections of HA, chondroitin, glucosamine

Not FDA-required, but recommended

**Supplements**

For general health, not disease treatment

A few examples: Summit Joint Performance® MoveX® Platinum® Conquer® VitaFlex® SmartFlex® And many more

INDICATIONS: For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION: There are no known contraindications to the use of intramuscular Adequan® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

*Trademarks are the property of their respective owners.
Ask your veterinarian about the difference

**FDA-approved drug requirements**

<table>
<thead>
<tr>
<th></th>
<th>Clinical safety &amp; efficacy</th>
<th>Consistent formulation</th>
<th>Advertising submission</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Must be proven</strong> in clinical trials and studies before going to market. <strong>No generic PSGAGs are approved by the FDA, so there is no other product just like Adequan but cheaper.</strong></td>
<td><strong>Manufacturer must acquire active ingredient from an FDA-inspected source, adhere to Good Manufacturing Practices, verify drug quality and purity, and maintain detailed consistency records for each batch.</strong></td>
<td><strong>Must submit all marketing, promotional and educational pieces to the FDA upon publication or dissemination.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Brand name and generic products must be proven in clinical trials and studies before going to market.</strong></td>
<td><strong>Manufacturers must adhere to Quality System Regulations, but the requirements for verifying ingredient sources and batch consistency are different from FDA-approved drugs.</strong></td>
<td><strong>Not required to submit marketing, promotional or educational materials. Should not be promoted as drugs.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Regulated differently by the FDA than prescription drugs. With different types requiring different levels of approval. Because devices may not have been clinically tested, they cannot be considered as “off-label” or “generic” replacements for drugs.</strong></td>
<td><strong>Use a compounding pharmacist who follows FDA Guidelines for Good Compounding Practices.</strong></td>
<td><strong>Not required to submit marketing, promotional or educational materials.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Not FDA-approved; although, FDA-approved drugs should be used in formulation. Not considered generic drugs.</strong></td>
<td><strong>No requirement for manufacturers to verify ingredient source, processes, product quality or batch consistency.</strong></td>
<td><strong>Not required to submit marketing, promotional or educational materials. Cannot make medical claims.</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Indications:** For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

**Important Safety Information:** There are no known contraindications to the use of intramuscular Adequan® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. **Warning:** Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Please see accompanying Full Prescribing Information or visit www.adequan.com.
Nothing else like it

As the only FDA-approved PSGAG for degenerative joint disease (DJD) in horses, Adequan® i.m. actually treats DJD, not just its clinical signs.¹²
Unlike any other joint product, Adequan i.m. has been proven to:¹³⁴

- Reduce inflammation
- Restore synovial joint lubrication
- Repair joint cartilage
- Reverse the disease process

As a prescription product, Adequan® reinforces the partnership between veterinarians and clients. By working closely with horse owners, veterinarians can help identify early signs of DJD and understand what works best to help keep horses moving.

Learn more at Adequan.com

What the experts are saying about product options

“I try to talk to clients, telling them I feel it’s a bigger bang for your buck if you go with the intramuscular Adequan [than unproven supplements].”—Dr. Robin Dabareiner

“The conversation I always have with a client is that I can’t tell you yes or no that it’s going to work for your horse. Some people swear by them. Some people think they don’t work at all. If I’m going to recommend that you spend your money, I want to have some research or solid proof that I’m not just throwing your money away.”—Dr. Zach Loppnow

“It feels like there’s a lot of time talking people down, a little bit, from what’s out there and what can be used [to treat DJD]. And that, by the way, if you add up what your feed through costs, you may be able to do a box of Adequan [i.m.] as an FDA-approved product.”—Dr. Kelly Tisher

For more expert commentary on DJD, click or visit EquiManagement.com/arah

Talk to your veterinarian to find out if Adequan i.m. is right for your horse.
Learn more at Adequan.com.

¹ Each of these experts are paid consultants of American Regent, Inc. The opinions expressed by the consultants may not be the opinions of American Regent Animal Health or American Regent, Inc.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Each 5 milliliters of Adequan® i.m. contains 500 mg of Polysulfated Glycosaminoglycan (PSGAG) and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. Sodium Chloride may be added to adjust tonicity.

PHARMACOLOGY: Polysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpals and hock joints.

INDICATIONS: Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpals and hock joints in horses.

DOSEAGE AND ADMINISTRATION: The recommended dose of Adequan® i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan® i.m. with other drugs or solvents.

CONTRAINDICATIONS: There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.


PRECAUTIONS: The safe use of Adequan® i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.

ANIMAL SAFETY: Toxicology studies were conducted in horses. Doses as high as 2.5,000 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.

STORAGE CONDITIONS: Store at 20°-25°C (68°-77°F). (See USP Controlled Room Temperature). Discard unused portion.

HOW SUPPLIED: Adequan® i.m. solution, 500 mg/mL (100 mg/mL) in a 5 mL single dose glass vial. NDC 10797-995-70 5 mL Single Dose Vials Packaged 7 vials per box

AMERICAN EQUINE, INC.
ANIMAL HEALTH
Shelby, NY 14167
(1-888-354-4857)

Approved by FDA under NADA # 140-901

SINGLE DOSE
Solution 500 mg/5 mL
For Intramuscular Use In Horses

MULTI-DOSE
Solution 100 mg/mL In a 50 mL Preserved Multi-Dose Vial
For Intramuscular Use In Horses Only. Not for Intra-Articular Use.